Sign in
Taking people in United StatesNo phase

Resistant potato starch for people with cirrhosis and hepatic encephalopathy

Tests resistant potato starch and its effect on gut bacteria in cirrhosis with hepatic encephalopathy.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
Status
Recruiting
People taking part
11 people, planned
Started
12 Jul 2024
Expected to end
28 Jan 2027
Type of study
Interventional
Treatments tested
  • Resistant Potato Starch
Record updated
30 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis (scarring of the liver) who had at least one episode of overt hepatic encephalopathy (confusion caused by liver disease) in the last year. Participants take resistant potato starch for four weeks.

Age
18 Years to 99 Years
Sex
All
Disease stage
Cirrhosis shown by liver biopsy, imaging or signs of worsening liver disease. At least one episode of overt hepatic encephalopathy in the last year, West Haven Criteria Grades II to IV. The episode may have had a trigger.
Earlier treatment
No lactulose in the last 4 weeks. No antibiotics taken by mouth that are absorbed by the gut, and none given by vein, in the last 4 weeks (rifaximin is allowed). No portosystemic shunt or transjugular intrahepatic portosystemic shunt placed in the last 3 months.
Biomarker or test result
Total bilirubin must not have been > 4 mg/dL in the last 3 months.

Main reasons for not taking part

  • Hospital stay in the last 4 weeks
  • Fluid in the belly that needs large drainage to manage
  • Alcohol (>1 alcoholic drink / week) or illegal drugs in the last 4 weeks
  • Inflammatory bowel disease, primary sclerosing cholangitis, or dementia or another primary memory and thinking disorder
  • Pregnancy or breast feeding, or allergy to resistant potato starch

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Able to provide consent, with signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical decompensation
  • History of at least one episode of overt Hepatic Encephalopathy (HE) in the last year; Defined by West Haven Criteria Grades II to IV; Can be precipitated Hepatic Encephalopathy (HE) episode
  • Sexually active women of childbearing potential enrolled in the study must agree to use a highly-effective method of contraception (defined in the protocol) for the duration of the study

Who cannot take part

  • Gut-absorbable or intravenous antibiotic therapy in the last 4 weeks (rifaximin is permitted)
  • Alcohol or illicit drug intake in the last 4 weeks; By history; Alcohol use will be characterized as >1 alcoholic drink / week
  • Prior diagnosis of dementia or other primary neurocognitive disorder
  • Placement of a portosystemic shunt or transjugular intrahepatic portosystemic shunt in the last 3 months (permissible if placed >3 months before enrollment)
  • History of inflammatory bowel disease
  • History of primary sclerosing cholangitis
  • Allergy to resistant potato starch
  • Total bilirubin in the last 3 months > 4 mg/dL
  • Hospitalization in the last 4 weeks
  • Current refractory ascites (requiring large volume paracentesis to manage ascites)
  • Anticipated antibiotics in the coming 4 weeks
  • Use of lactulose in the last 4 weeks
  • Pregnancy or breast feeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • Mayo ClinicRochester, United StatesContact: Jenny ObstTaking people

About the trial

What the trial wants to find out

This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy.

Read full original descriptionShow less

The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.

The group in the trial

  • Resistant potato starchTreatment being tested

    This will be taken for four weeks by enrolled participants.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
Plain-language title
Resistant potato starch for people with cirrhosis and hepatic encephalopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06425380, who can take part
Record updated
30 January 2026